AIM ImmunoTech Inc is trading at $0.38 (5.1% down) in pre-market, extending a sharp selloff triggered by a major capital restructuring aimed at maintaining its exchange listing.
- The move follows a heavily dilutive equity and warrant financing package tied to a NYSE American compliance-driven restructuring of the company's capital structure.
- The stock plummeted approximately 86% in the prior regular session as investors reacted to the substantial dilution and listing-related changes.
- The current price action reflects continued downward pressure as the market absorbs the impact of the newly issued securities and structural shifts.